Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.33
-0.0700-5.00%
Volume:649.26K
Turnover:851.80K
Market Cap:56.54M
PE:-0.67
High:1.42
Open:1.37
Low:1.25
Close:1.40
Loading ...

Repare Therapeutics Inc - Exploring Partnerships for Lunre+Camo

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Inc: $152.8 Mln in Cash and Cash Equivalents and Marketable Securities Provides Runway to Late-2027

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Inc: Company Reducing Its Workforce by Approximately 75%

THOMSON REUTERS
·
03 Mar

Repare Therapeutics FY Income From Operations USD -93.523 Million

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

LifeSci Capital Remains a Hold on Repare Therapeutics (RPTX)

TIPRANKS
·
26 Feb

Repare Therapeutics Chief Medical Officer to Leave

MT Newswires Live
·
26 Feb

Repare Therapeutics Inc - to Reduce Workforce by Approximately 75%

THOMSON REUTERS
·
25 Feb

Repare Therapeutics Inc - Expects $21 Million in Annual Operating Expense Savings

THOMSON REUTERS
·
25 Feb

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Zacks
·
25 Feb

Catherine Wood's Strategic Reduction in Repare Therapeutics Inc Holdings

GuruFocus
·
15 Feb

Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks
·
24 Jan

Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
21 Jan

Strategic Shift and Uncertainties Lead to Hold Rating for Repare Therapeutics

TIPRANKS
·
12 Jan

Stifel Nicolaus Sticks to Their Buy Rating for Repare Therapeutics (RPTX)

TIPRANKS
·
11 Jan

Repare Therapeutics price target lowered to $3 from $4 at Stifel

TIPRANKS
·
11 Jan

Repare Therapeutics Shifts Focus to Phase 1 Programs

TIPRANKS
·
10 Jan

Piper Sandler Sticks to Their Buy Rating for Repare Therapeutics (RPTX)

TIPRANKS
·
10 Jan

Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials

MT Newswires Live
·
10 Jan